nueva página del texto (beta)
Inglés (pdf)
Artículo en XML
Referencias del artículo
Traducción automática
Enviar artículo por email
Citado por SciELO 
Similares en
SciELO 
Permalink
INTRODUCTION
The cost of performing a percutaneous coronary intervention is highly variable because a large number of materials and human resources are to be considered, the stent is a fundamental factor. In developing countries, the cost of this technology is expensive for the patient as well as for the health systems, which have promoted the development of local technology to help meet the requirements of these devices1. Recently, several countries have started developing their own stents due to the high cost of importing and distributing this technology2-4.
We have an extensive experience on successfully working with platinum/iridium stents manufactured by hand for coronary, aortic, and peripheral arteries5-7. As of 2014, a group from the National Institute of Cardiology (INC) associated with GSE Biomedical and the Technological Institute of Higher Studies of Monterrey (ITESM), all in Mexico, worked on the design and development of a Mexican coronary stent, using as a guide the methodology based on “quality function deployment.” We compared the needs of the interventional cardiologist as the user, against the technical or engineering requirements, and compared with the maximum goal to be achieved considering the biophysical characteristics of commercial stents. In the design process, we agreed that among other characteristics, the INC-01 stent should have a cobalt platform and chrome L605 (Co-Cr), according to the international standard with struts of 80 µm thickness, expanded by balloon, and with the performance equaling that of the second-generation stent or higher as per to the requirements of the ISO (ISO 25539-2: 2008) (Fig. S1). Design and testing proposals were made to select the geometric design of the stent based on finite element tests by computer (Fig. 1A).
Figure 1 (A) Finite element tests by computer. (B) Thrombotic occlusion of the anterior descending coronary artery (red arrow). (C) Angiography after implanting a 3.5 × 18 mm INC-01 bare-metal stent model (red arrow). (D) Intravascular ultrasound. In the image on the left, the distal reference diameter is observed and in the image on the right, the stent implanted with adequate expansion and apposition.
METHODS
In vitro tests
About 15 in vitro tests were carried out according to the ISO standard (radial force, flexibility, elongation deformation, and longitudinal shortening, among others) and they showed adequate and consistent characteristics with the computational tests8.
In vivo tests
Tests were performed on a porcine model with 10 live porcine specimens of the Yorkshire breed, obtaining technical success in 100% of the evaluated parameters. We demonstrated that the INC-01 bare-metal stent has physical, biological, and histological characteristics similar to those found in commercial metallic stents9.
With the above-mentioned results, and after submitting the human protocol for review to the Medical Ethics and Research Committee, the implementation of a first-in-man study was decided with prior informed consent from patients and following the recommendations of the Declaration of Helsinki.
PRESENTATION OF CASES
With prior informed consent, the INC-01 bare-metal stent was implanted in three patients from the INC following the international standards of care for ischemic heart disease. They were performed by radial access in two cases and femoral in one. Adequate stent expansion was confirmed by an intracoronary ultrasound with a 40 MHz Volcano® probe. The patients were followed up every week for 1 month, then by telephone call every month, and finally by an in-person appointment after 6 months to perform coronary angiography and coronary ultrasound.
Case 1
A 67-year-old man, an active smoker but without chronic degenerative diseases, was admitted with a diagnosis of acute anteroseptal myocardial infarction. The coronary angiography identified thrombotic occlusion of the anterior descending artery in its proximal segment (Fig. 1B and C). Pre-dilation with a 3.0 × 20 mm conventional balloon was performed, and subsequently, a 3.5 × 18 mm INC-01 bare-metal stent was implanted at nominal pressure, confirming adequate expansion and apposition of it by intracoronary ultrasound (Fig. 1D). The patient was discharged 72 h after coronary intervention.
Case 2
A 64-year-old man, diabetic with hypercholesterolemia and an active smoker, was admitted with a diagnosis of inferior non-reperfused myocardial infarction. Coronary angiography was performed, finding trivascular coronary disease with involvement of the left main coronary artery, with failed angioplasty to the right coronary artery. The heart team considered the case unsuitable for revascularization surgery, so it was decided to perform percutaneous coronary revascularization. Intracoronary ultrasound was performed, and it was decided to implant a 3.5 × 18 mm INC-01 bare-metal stent at nominal pressure to impact it at 14 atmospheres (4.11 mm) (Fig. 2A); intravascular ultrasound (IVUS) was also performed, thereby confirming adequate expansion and complete apposition (Fig. 2B). Furthermore, another 2.5 × 24 mm commercial bare-metal stent was implanted in the middle segment of the anterior descending artery, without any complications. The patient was closely monitored for 72 h and then discharged. No ischemia was found in the right coronary artery.
Figure 2 (A) On the left, lesion in the proximal segment of the anterior descending and the left main coronary artery (red arrow); on the right, post-implantation angiography is observed (red arrow). (B) The examination by intravascular ultrasound: on the left, adequate expansion of the stent is observed in the proximal segment of the anterior descending coronary artery; to the right, adequate stenting of the left main coronary artery. (C) On the left, a critical lesion was seen in the middle segment of the anterior descending coronary artery (red arrow); to the right, angiography after implantation of the INC-01 stent (red arrow). (D) On the left, the distal reference image is seen, and, on the right, the stent implanted properly.
Case 3
A 38-year-old hypertensive man, with a history of non-reperfused anteroseptal myocardial infarction and coronary lesions in the anterior descending and right coronary arteries, was admitted for angioplasty scheduled after a nuclear medicine study that reported an anteroseptal infarction with anterior and inferior ischemia. Therefore, a 3.5 × 18 mm INC-01 bare-metal stent was implanted in the middle segment of the anterior descending artery (Fig. 2C) at nominal pressure, and symmetrical expansion and apposition were corroborated by intracoronary ultrasound (Fig. 2D); a 3.0 drug-eluting stent was subsequently implanted 33 mm in the middle segment of the right coronary artery. The patient was closely monitored and was discharged home symptomless after 24 h.
Clinical follow-up
At 10 months of follow-up, the three patients have remained alive. One of them was admitted with thoracic pain of prolonged exertion (not typical angina) and has been followed with cardiac rehabilitation. At present, he is symptomless without angina or equivalent, with functional Class I of the New York Heart Association Classification. The other two patients remained symptomless and without clinical events.
DISCUSSION
In this pilot study of the INC-01 bare-metal stent, the adequate functionality of the device was confirmed, with a satisfactory advancement profile, good navigation, radial strength, and symmetrical expansion. The stent had no complications in the immediate post-implantation period or short-term follow-up, with a strict monitoring of the clinical status of patients with periodic visits, so it is considered that at present, the INC-01 bare-metal stent results are very promising. Therefore, a clinical protocol in humans that include a larger sample size and follow-up at different points with angiography and IVUS to evaluate safety and efficacy of the stent has been designed and approved by the ethics and scientific committees of our institute. The protocol has been admitted by the COFEPRIS (regulatory body for the use of medicines and medical devices in our country), which is in accordance to good international manufacturing and sterilization practices.
This study is our first experience in human implantation of the INC-01 stent, where we only evaluated clinical data. However, it must be replicated in a larger sample, and necessarily, we should have a follow-up with angiography and IVUS.
Supplementary data
Supplementary data are available at Revista de Investigación Clínica online (www.clinicalandtranslationalinvestigation.com). These data are provided by the corresponding author and published online for the benefit of the reader. The contents of supplementary data are the sole responsibility of the authors.
